Etcamah Grabs FDA Approval for Advanced Breast Cancer with ESR1 Mutations
The accelerated approval follows a phase 3 trial showing a 56% progression-free survival improvement and a median 16-month response, the FDA said.
7 Articles
7 Articles
US FDA approves AstraZeneca’s new breast cancer pill Etcamah: Dosage, high risk and side effects — All you need to know
The drug, known as camizestrant, can be used in combination with other cancer medicines in patients who have a genetically driven form of metastatic breast cancer. AstraZeneca said camizestrant, which will go by the brand name ETCAMAH.
<p>A new breast cancer pill has been approved in the United States, despite previous doubts from FDA experts, the FDA has allowed AstraZeneca to sell Etcamah to patients with a certain mutation. The drug can delay the progression of the disease more than 6 months.</p>
AstraZeneca's breast cancer pill, known as camizestrant, will be marketed under the name Etcamah.
The U.S. Regulatory Agency for Drugs and Food (FDA) approved a treatment for advanced breast cancer developed by AstraZeneca. The agency informed on Friday (4) that it granted accelerated approval to Etcamah of AstraZeneca, a medicine commonly known as camizestrant, in combination with a CDK4/6 inhibitor to treat patients eligible for breast cancer. Exclusive material for subscribers. To have full access, access the link of the material and regi…
Etcamah grabs FDA approval for advanced breast cancer with ESR1 mutations
The FDA has granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.The approval for camizestrant (Etcamah, AstraZeneca) is dependent on the detection of an ESR1 mutation during aromatase and CDK4/6 inhibitor therapy.
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
